Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2021

Bomben Riccardo, Zucchetto Antonella, Gentile Massimo, Gattei Valter

Abstract excerpt

Patients with chronic lymphocytic leukemia carrying a single TP53 hit (chromosome 17p deletion or single TP53 mutation) demonstrate excellent progression-free survival and overall survival on ibrutinib compared with cases harboring multiple TP53 hits. Testing TP53 deletion/mutation combining FISH and deep next-generation sequencing should be performed for a correct patient evaluation.See related article by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Piperidines

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 34127506
DOI: 10.1158/1078-0432.CCR-21-1750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?PMID 34127506Read ↗

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.Semantic proximity Read ↗

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.Semantic proximity Read ↗

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.Semantic proximity Read ↗

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.Semantic proximity Read ↗

Ibrutinib treatment of CLL: the cancer fights back.Semantic proximity Read ↗

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.Semantic proximity Read ↗

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretationSemantic proximity Read ↗

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.